Global Hereditary Angioedema Therapeutics Market Share

Statistics for the 2023 & 2024 Global Hereditary Angioedema Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Global Hereditary Angioedema Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Genetic Disorder Drugs Research Hereditary Angioedema Therapeutic Industry Market Share

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Hereditary Angioedema Therapeutics Industry

The hereditary angioedema therapeutics market is highly consolidated in terms of competition and consists of limited major players. Some of the companies currently dominating the market are CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., BioCryst Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Ionis Pharmaceuticals, KalVista Pharmaceuticals Inc., and Adverum Biotechnologies Inc.

Hereditary Angioedema Market Leaders

  1. CSL Behring

  2. Takeda Pharmaceutical Company Limited

  3. Pharming Healthcare Inc.

  4. Sanofi

  5. BioCryst Pharmaceuticals Inc.

*Disclaimer: Major Players sorted in no particular order

CSL Behring, Takeda Pharmaceutical Company Limited, Pharming Healthcare Inc., Sanofi, BioCryst Pharmaceuticals Inc.

Hereditary Angioedema Treatment Market Report Snapshots

Hereditary Angioedema Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)